Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DTIL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPrecision BioSciences shareholders approve 3.8M share increase to equity plan, officer liability limits
Filed May 26, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
medium
Shareholders approved adding 3.8 million shares to the 2019 equity compensation plan, expanding the pool available for employee stock grants and options. This increases potential shareholder dilution from future equity awards.
Item 5.03: Equity Plan verify on EDGAR → -
medium
Charter amendment approved to limit personal liability of certain officers for breaches of fiduciary duty, as permitted under Delaware law. The amendment became effective May 22, 2026.
Item 5.03: Charter Amendment verify on EDGAR → -
low
Two Class I directors elected to serve until 2029: Melinda Brown (14.3M votes for) and Geno Germano (14.3M votes for). Both received majority support from shareholders.
Item 5.07: Director Elections verify on EDGAR → -
low
Deloitte & Touche LLP ratified as independent auditor for 2026 with 22.2 million votes in favor, representing continuity in the company's external audit relationship.
Item 5.07: Auditor verify on EDGAR →
Summary
Precision BioSciences held its annual shareholder meeting on May 21, 2026, where investors approved two material governance changes. First, the company expanded its 2019 equity incentive plan by 3.8 million shares, increasing the pool available for employee compensation through stock grants and options.
This represents additional potential dilution for existing shareholders as the company uses equity to attract and retain talent. Second, shareholders approved a charter amendment limiting officer liability for certain breaches of fiduciary duty, bringing the company in line with recent Delaware corporate law changes that allow such protections.
For retail investors, the equity plan expansion is the more immediate concern, as it directly affects ownership percentages. The 3.8 million share increase should be evaluated against the company's current share count and burn rate of equity compensation. The officer exculpation provision is a governance matter that reduces personal liability risk for executives, which could affect accountability but is increasingly standard among Delaware corporations. Watch for the company's next proxy filing to see how quickly it utilizes the expanded equity pool and whether compensation practices change materially.
Section-by-Section Diff
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
Item 5.03 — Amendments to Articles of Incorporation or Bylaws filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On May 22, 2026, the Company filed the 2026 Amendment with the Secretary of State of the State of Delaware, and the 2026 Amendment became effective upon filing.
The charter amendment was filed with Delaware on May 22, 2026 and took effect immediately upon filing. This timing is relevant because it establishes when the officer liability protections became operative.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Annual meeting held May 21, 2026: two directors elected, auditor ratified, executive compensation approved, equity plan amended, charter updated.
Added in current filing · verify on EDGAR →
Approval of the amendment and restatement of the Company’s 2019 Incentive Award Plan.
Shareholders approved amendments to the 2019 equity incentive plan with 11,170,635 votes for versus 8,145,992 against. This likely increases the share reserve or modifies terms for employee equity compensation, which can affect shareholder dilution.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
Melinda Brown and Geno Germano were elected as Class I directors
Two Class I directors were elected to serve until the 2029 annual meeting. Melinda Brown received 14,348,888 votes for and 4,978,645 withheld; Geno Germano received 14,288,270 votes for and 5,039,263 withheld. Both were elected based on majority support.
Added in current filing · verify on EDGAR →
Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
Shareholders ratified Deloitte & Touche LLP as the independent auditor for 2026 with 22,198,597 votes for, 99,879 against, and 6,391 abstained. This is a routine annual approval confirming continuity in external audit relationships.
Added in current filing · verify on EDGAR →
Approval of an amendment to the Company’s Certificate of Incorporation to reflect changes in Delaware law regarding officer exculpation.
Shareholders approved a charter amendment related to Delaware law changes on officer exculpation with 17,909,703 votes for. This updates liability protections for corporate officers, aligning governance documents with recent Delaware statutory changes.
Event · Item 9.01 — Financial Statements and Exhibits
Precision BioSciences amended its certificate of incorporation and restated its 2019 equity incentive plan.
Added in current filing · verify on EDGAR →
Certificate of Amendment to Amended and Restated Certificate of Incorporation of Precision BioSciences, Inc.
The company filed an amendment to its certificate of incorporation. The 8-K does not disclose the specific changes made, but amendments typically involve changes to authorized shares, corporate name, or governance provisions. Investors should review the attached exhibit to understand the material terms of the amendment.
Added in current filing · verify on EDGAR →
Precision BioSciences, Inc. 2019 Incentive Award Plan, as Amended and Restated.
The company amended and restated its 2019 equity incentive plan. Such amendments often involve increasing the share reserve available for equity grants, modifying vesting terms, or updating plan administration provisions. The specific changes are not disclosed in the 8-K body but would be detailed in the attached exhibit.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify